지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.94 No.4
- 발행연도
- 2018.4
- 수록면
- 196 - 202 (7page)
이용수
초록· 키워드
오류제보하기
Purpose: An oxaliplatin-based regimen is the most common adjuvant chemotherapy for patients with stage II/III colorectal cancer, but many patients experience dose reduction or early termination of chemotherapy due to side effects. We conducted this study to verify the range of reduction with oncologic safety.
Methods: Patients with stage II/III colorectal cancer who received adjuvant FOLFOX chemotherapy were enrolled in this study. The total amount of oxaliplatin administered per patient was calculated as a percentile based on 12 cycles of fulldose FOLFOX as a standard dose. The cutoff values showing significant differences in survival were calculated, and the clinicopathologic outcomes of patient groups classified by the value were compared.
Results: Among a total of 611 patients, there were 107 stage II patients, and 504 stage III patients. At 60% of the standard dose of oxaliplatin, the patients in the dose reduction group were older (62 years vs. 58 years, P = 0.003), had lower body mass index (BMI) (23.1 kg/m2 vs. 24.0 kg/m2, P = 0.005), and were more exposed to neoadjuvant treatment (18.0% vs. 9.1%, P = 0.003) in comparison to the standard group. At 60% of the standard dose, there were no significant differences in 5-year disease-free survival (DFS) and overall survival (OS) between the 2 groups (5-year DFS: 73.5% vs. 74.2%, P = 0.519; 5-year OS: 71.9% vs. 81.5%, P = 0.256, respectively).
Conclusion: Patients with old age, low BMI, and more frequent exposure to neoadjuvant treatment tended to show lower compliance with chemotherapy. More than 60% dose should be administered to patients with stage II/III colorectal cancer as adjuvant chemotherapy to achieve acceptable oncologic outcomes.
Methods: Patients with stage II/III colorectal cancer who received adjuvant FOLFOX chemotherapy were enrolled in this study. The total amount of oxaliplatin administered per patient was calculated as a percentile based on 12 cycles of fulldose FOLFOX as a standard dose. The cutoff values showing significant differences in survival were calculated, and the clinicopathologic outcomes of patient groups classified by the value were compared.
Results: Among a total of 611 patients, there were 107 stage II patients, and 504 stage III patients. At 60% of the standard dose of oxaliplatin, the patients in the dose reduction group were older (62 years vs. 58 years, P = 0.003), had lower body mass index (BMI) (23.1 kg/m2 vs. 24.0 kg/m2, P = 0.005), and were more exposed to neoadjuvant treatment (18.0% vs. 9.1%, P = 0.003) in comparison to the standard group. At 60% of the standard dose, there were no significant differences in 5-year disease-free survival (DFS) and overall survival (OS) between the 2 groups (5-year DFS: 73.5% vs. 74.2%, P = 0.519; 5-year OS: 71.9% vs. 81.5%, P = 0.256, respectively).
Conclusion: Patients with old age, low BMI, and more frequent exposure to neoadjuvant treatment tended to show lower compliance with chemotherapy. More than 60% dose should be administered to patients with stage II/III colorectal cancer as adjuvant chemotherapy to achieve acceptable oncologic outcomes.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (22)
참고문헌 신청
[학술지(정기간행물)] - Sharif S / 2008 / FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon ancer / Cancer Invest 26 : 956 ~ 963
[학술지(정기간행물)] - Chau I / 2002 / Chemotherapy in colorectal cancer: new options and new challenges / Br Med Bull 64 : 159 ~ 180
[학술지(정기간행물)] - Andre T / 2004 / Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer / N Engl J Med 350 : 2343 ~ 2351
[학술지(정기간행물)] - Andre T / 2007 / Current status of adjuvant therapy for colon cancer / Gastrointest Cancer Res 1 : 90 ~ 97
[학술지(정기간행물)] - Rothenberg ML / 2000 / Efficacy of oxaliplatin in the treatment of colorectal cancer / Oncology (Williston Park) 14 (12 Suppl 11) : 9 ~ 14
[학술지(정기간행물)] - Chau I / 2002 / Chemotherapy in colorectal cancer: new options and new challenges / Br Med Bull 64 : 159 ~ 180
[학술지(정기간행물)] - Andre T / 2004 / Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer / N Engl J Med 350 : 2343 ~ 2351
[학술지(정기간행물)] - Andre T / 2007 / Current status of adjuvant therapy for colon cancer / Gastrointest Cancer Res 1 : 90 ~ 97
[학술지(정기간행물)] - Rothenberg ML / 2000 / Efficacy of oxaliplatin in the treatment of colorectal cancer / Oncology (Williston Park) 14 (12 Suppl 11) : 9 ~ 14
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
Journal of Pathology and Translational Medicine
2015 .01
-
The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Quality of life changes during adjuvant chemotherapy in patients with colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .06
-
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer
Annals of Surgical Treatment and Research
2015 .08
-
[Colorectal] What is the Role of Adjuvant Chemotherapy in Elderly Patients with Colorectal Cancer?
대한외과학회 학술대회 초록집
2022 .11
-
Comparison of the Beneficial Effects of Adjuvant Chemotherapy among Young and Old Aged Breast Cancer Patients
Journal of Breast Disease
2019 .01
-
Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
Cancer Research and Treatment
2018 .01
-
Adjuvant Chemotherapy and Prognostic Factors in Stage II Colon Cancer - Izmir Oncology Group Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Guideline of Adjuvant Chemotherapy - Colorectal Cancer
대한외과학회 학술대회 초록집
2017 .11
-
Prognostic factors and suggestive adjuvant chemotherapy in patients with stage II colorectal cancer
대한외과학회 학술대회 초록집
2017 .11
-
Adjuvant oxaliplatin-based chemotherapy effect after treatment of colorectal hepatic metastasis
Annals of Surgical Treatment and Research
2021 .09
-
Effects of 7~11 cycles adjuvant FOLFOX chemotherapy on the prognosis of patients with stage III colon cancer
의생명과학
2019 .01
-
Adjuvant chemotherapy in patients with stage II colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Long-term Efficacy of S-1 Monotherapy or Capecitabine plus Oxaliplatin as an Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancers after Curative Gastrectomy: Propensity Score-Matched Multicenter Cohort Study
대한임상종양학회 학술대회지
2020 .07
-
Early Initiation and Reduced Cycles of Adjuvant Chemotherapy [FOLFOX4] after Minimally Invasive Colorectal Cancer Surgery in Elderly Patient
대한임상종양학회 학술대회지
2016 .02
-
The Effect of Adjuvant Chemotherapy in the Elderly Patients Receiving Colorectal Cancer Surgeries: A Propensity Score-Matched Analysis
대한외과학회 학술대회 초록집
2021 .05
-
Effect of age on laparoscopic surgery and adjuvant chemotherapy in elderly colorectal cancer patients
대한외과학회 학술대회 초록집
2019 .10
-
Is Adjuvant Chemotherapy Beneficial for Oldest-old (Aged 80 Years or Older) Patients with Stage II Colon Cancer?
대한외과학회 학술대회 초록집
2020 .11
-
Adjuvant chemotherapy for patients with stage II high-risk and III colon cancer: Hindering factors to adherence and impact on long-term survival
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2021 .06
-
Increased NLR during Adjuvant Chemotherapy Is Related to Poor Prognosis in Stage II,III Gastric Cancer Patients
대한외과학회 학술대회 초록집
2021 .05
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2018-514-001913126